AR044983A1 - Solidos con capa de difusion modulada - Google Patents
Solidos con capa de difusion moduladaInfo
- Publication number
- AR044983A1 AR044983A1 ARP040102322A ARP040102322A AR044983A1 AR 044983 A1 AR044983 A1 AR 044983A1 AR P040102322 A ARP040102322 A AR P040102322A AR P040102322 A ARP040102322 A AR P040102322A AR 044983 A1 AR044983 A1 AR 044983A1
- Authority
- AR
- Argentina
- Prior art keywords
- diffusion layer
- drug
- solid
- modulated
- modulated diffusion
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Sólidos con capa de difusión modulada que incluyen un excipiente y una sal soluble de un fármaco básico poco soluble; una sal soluble de un fármaco ácido poco soluble; o un fármaco no ionizable poco soluble, que son útiles, por ejemplo, para el suministro mejorado de fármacos. Reivindicación 1: Un sólido con capa de difusión modulada que comprende una sal soluble de un fármaco básico que presenta una solubilidad de al menos 50 microgramos/ml en un fluido acuoso a pH 6 a 7 a 25° C y un excipiente seleccionado entre el grupo que consiste de excipientes ácidos, excipientes solubilizantes, y combinaciones de los mismos; en los cuales por lo menos a un valor de pH, la tasa de disolución intrínseca del sólido con capa de difusión modulada es por lo menos 10 % mayor que la tasa de disolución intrínseca de la sal de fármaco sola al mismo pH, y en los cuales las tasas de disolución se determinan a 25° C en agua a un pH de 1 a 7 empleando el método del disco rotatorio. Reivindicación 8: Una composición que comprende: un sólido con capa de difusión modulada de acuerdo con cualquiera de las reivindicaciones 1 7; y un inhibidor del crecimiento de los cristales. Reivindicación 11: Un método para aumentar la biodisponibilidad de un fármaco que comprende proporcionar un sólido con capa de difusión modulada de acuerdo con cualquiera de las reivindicaciones 1 a 7. Reivindicación 12: Un método para preparar un sólido con capa de difusión modulada de acuerdo con cualquiera de la reivindicaciones 1, 4 y 7, el método que comprende preparar partículas que incluyen una sal soluble de un fármaco básico que presenta una solubilidad de al menos 50 microgramos/ml en un fluido acuoso a pH 6 a 7 a 25° C y un excipiente seleccionado entre el grupo que consiste de excipientes ácidos, excipientes solubilizantes y combinaciones de los mismos.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US48420503P | 2003-07-01 | 2003-07-01 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR044983A1 true AR044983A1 (es) | 2005-10-12 |
Family
ID=34062033
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP040102322A AR044983A1 (es) | 2003-07-01 | 2004-07-01 | Solidos con capa de difusion modulada |
Country Status (9)
Country | Link |
---|---|
US (1) | US20050042291A1 (es) |
EP (1) | EP1643948A1 (es) |
JP (1) | JP2007527394A (es) |
AR (1) | AR044983A1 (es) |
BR (1) | BRPI0412190A (es) |
CA (1) | CA2531116A1 (es) |
MX (1) | MXPA06000178A (es) |
TW (1) | TW200514576A (es) |
WO (1) | WO2005004763A1 (es) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100777169B1 (ko) | 2001-01-29 | 2007-11-16 | 시오노기세이야쿠가부시키가이샤 | 5-메틸-1-페닐-2-(1h)-피리돈을 활성 성분으로서함유하는 의약 제제 |
NZ591443A (en) * | 2005-09-22 | 2013-04-26 | Intermune Inc | Granule formation of pirfenidone and pharmaceutically acceptable excipients |
US8486452B2 (en) | 2007-07-20 | 2013-07-16 | Mylan Pharmaceuticals Inc. | Stabilized tolterodine tartrate formulations |
JP6158702B2 (ja) * | 2010-04-09 | 2017-07-05 | ブリストル−マイヤーズ・スクイブ・ホールディングス・アイルランドBristol−Myers Squibb Holdings Ireland | pHの影響を改善したアタザナビル硫酸塩製剤 |
DE102011113749A1 (de) * | 2011-09-14 | 2013-03-14 | Aicuris Gmbh & Co. Kg | Sulfonsäuresalze Heterocyclylamid-substituiertr Imidazole |
RU2630617C2 (ru) * | 2011-10-18 | 2017-09-11 | Аскат Инк. | Фармацевтическая композиция |
CA2937365C (en) | 2016-03-29 | 2018-09-18 | F. Hoffmann-La Roche Ag | Granulate formulation of 5-methyl-1-phenyl-2-(1h)-pyridone and method of making the same |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU4028772A (en) * | 1971-04-02 | 1973-09-27 | Merck & Co., Inc | Chemical processes |
US4355091A (en) * | 1980-08-25 | 1982-10-19 | Polaroid Corporation | Polymeric neutralizing layer with temporary crosslinks from an organo-metallic crosslinking agent |
IT1255792B (it) * | 1992-08-05 | 1995-11-16 | Bayer Italia Spa | Composizioni farmaceutiche per la somministrazione orale di diidropiridine in forma di bevanda |
US6077850A (en) * | 1997-04-21 | 2000-06-20 | G.D. Searle & Co. | Substituted benzopyran analogs for the treatment of inflammation |
ZA984514B (en) * | 1997-05-29 | 1998-11-30 | Merck & Co Inc | Hiv protease inhibitor |
CA2328703C (en) * | 1998-06-11 | 2007-10-30 | Pharmacia & Upjohn Company | Delavirdine tablet formulation |
BR0009176A (pt) * | 1999-03-24 | 2001-12-18 | Fmc Corp | Partìcula granular, forma de dosagem, métodopara preparar uma partìcula granular, misturaseca, e, formulação granular |
EP1712222A3 (en) * | 1999-12-23 | 2012-06-20 | Pfizer Products Inc. | Pharmaceutical compositions providing enhanced drug concentrations |
MXPA03011784A (es) * | 2001-06-22 | 2004-04-02 | Pfizer Prod Inc | Composiciones farmaceuticas de dispersiones de farmacos y polimeros neutros. |
-
2004
- 2004-06-29 BR BRPI0412190-2A patent/BRPI0412190A/pt not_active IP Right Cessation
- 2004-06-29 WO PCT/US2004/021143 patent/WO2005004763A1/en active Search and Examination
- 2004-06-29 CA CA002531116A patent/CA2531116A1/en not_active Abandoned
- 2004-06-29 MX MXPA06000178A patent/MXPA06000178A/es unknown
- 2004-06-29 JP JP2006518756A patent/JP2007527394A/ja not_active Abandoned
- 2004-06-29 US US10/881,712 patent/US20050042291A1/en not_active Abandoned
- 2004-06-29 EP EP04777364A patent/EP1643948A1/en not_active Withdrawn
- 2004-07-01 AR ARP040102322A patent/AR044983A1/es not_active Application Discontinuation
- 2004-07-01 TW TW093119910A patent/TW200514576A/zh unknown
Also Published As
Publication number | Publication date |
---|---|
TW200514576A (en) | 2005-05-01 |
WO2005004763A1 (en) | 2005-01-20 |
JP2007527394A (ja) | 2007-09-27 |
CA2531116A1 (en) | 2005-01-20 |
BRPI0412190A (pt) | 2006-08-22 |
US20050042291A1 (en) | 2005-02-24 |
MXPA06000178A (es) | 2006-04-11 |
EP1643948A1 (en) | 2006-04-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ECSP055938A (es) | Formulaciones farmaceuticas liquidas de palonosetron | |
CY1105771T1 (el) | Φαρμακευτικες συνθεσεις εφαρμογης στον βλεννογονο | |
ATE493973T1 (de) | Irbesartan enthaltende pharmazeutische zusammensetzung | |
CO5560580A2 (es) | Formulaciones de sucralosa para disumular sabores desagradables | |
CL2010000816A1 (es) | Formulacion adecuada para administracion subcutanea que comprende al menos 100 mg/ml de ctlaig, un azucar, y un portador acuoso farmaceuticamente estable; articulo de fabricacion que comprende al menos un recipiente que contiene la formulacion antes mencionada. (divisional solicitud n° 3597-06) | |
CO5640120A2 (es) | Formulacion y metodods para el tratamiento de trombocitemia | |
ES2531215T3 (es) | Sistemas de administración de fármacos que comprenden un agente de bloqueo selectivo de la serotonina 5-HT3 débilmente básico y ácidos orgánicos | |
PE20070377A1 (es) | Formulaciones liquidas para la administracion controlada de derivados de bencisoxazol | |
AR068302A1 (es) | Peptidos para vacunas para canceres que expresan antigenos asociados con tumores | |
UY27273A1 (es) | Solución oral de arilpiprazol | |
AR062321A1 (es) | Sistema de liberacion controlada y metodo para fabricarlo | |
WO2009066146A3 (en) | Stable solutions of sparingly soluble actives | |
MX2007011039A (es) | Sistema de solvente para aumentar la solubilidad de agentes farmaceuticos. | |
PT1299107E (pt) | Solucoes estaveis muito concentradas de meloxicam | |
NI200600146A (es) | Composición farmacéutica de vinflunina para administración parenteral, proceso de preparación y su uso | |
AR044983A1 (es) | Solidos con capa de difusion modulada | |
NO20052100L (no) | Raloksifensalt I | |
AR051803A1 (es) | Compuestos organicos | |
ES2344730T3 (es) | Composicion farmacologica para administracion nasal de fentanilo. | |
ECSP066318A (es) | Composición para la liberación de una base debil por un periodo extendido de tiempo | |
NO20025277D0 (no) | Farmasöytisk administreringsform for peptider, dens fremstilling samt anvendelse | |
AR041945A1 (es) | Sistema terapeutico multicapa de administracion a traves de las mucosas | |
EA200300406A1 (ru) | Фармацевтическая композиция дронедарона для парентерального введения | |
WO2006095363A3 (en) | Injectable preparations of diclofenic and its pharmaceutically acceptable salts | |
ES2531241T3 (es) | Composición farmacéutica líquida estable a base de trazodona |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |